Overview

A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and effectiveness of fluoxetine flexible dosing in the treatment of MDD in adult Japanese participants. Participants who complete the short-term treatment phase of Study B1Y-JE-HCLV (NCT#: NCT01808612) will be allowed to enroll in this study, and receive fluoxetine treatment for an additional 52 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Fluoxetine